2 research outputs found
Additional file 1: Figure S1. of Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
Adjusted change from baseline in FEV1 over time on Day 14 (mITT population). Figure S2. LSM difference in FEV1 AUC0–12 on Day 14, vs placebo MDI (mITT population). (DOCX 437 kb
Additional file 1: of A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspensionâ„¢ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease
Study design; Additional Fig. 1. Study design schematic; Additional Fig. 2. Mean change from baseline in PEFR over time by treatment on Day 7 (mITT population); Additional Fig. 3. Mean change from baseline FVC over time by treatment on Day 7 (mITT population); Additional Table 1. Secondary efficacy endpoints: Days 1 and 7 – FF 9.6 μg and FF 7.2 μg comparisons (mITT population). (DOCX 466 kb